1
|
Cox ST, Patterson W, Duggleby R, Jones OJR, Madrigal JA, Querol S, Salvador FR, Mata MJH, Volt F, Gluckman É, Szydlo R, Danby RD, Hernandez D. Impact of donor NKG2D and MICA gene polymorphism on clinical outcomes of adult and paediatric allogeneic cord blood transplantation for malignant diseases. Eur J Haematol 2024. [PMID: 38511389 DOI: 10.1111/ejh.14202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 02/09/2024] [Accepted: 02/16/2024] [Indexed: 03/22/2024]
Abstract
OBJECTIVES NKG2D is an activating receptor expressed by natural killer (NK) and CD8+ T cells and activation intensity varies by NKG2D expression level or nature of its ligand. An NKG2D gene polymorphism determines high (HNK1) or low (LNK1) expression. MICA is the most polymorphic NKG2D ligand and stronger effector cell activation associates with methionine rather than valine at residue 129. We investigated correlation between cord blood (CB) NKG2D and MICA genotypes and haematopoietic stem cell (HSC) transplant outcome. METHODS We retrospectively studied 267 CB HSC recipients (178 adult and 87 paediatric) who underwent transplant for malignant disease between 2007 and 2018, analysing CB graft DNA for NKG2D and MICA polymorphisms using Sanger sequencing. Multivariate analysis was used to correlate these results with transplant outcomes. RESULTS In adult patients, LNK1 homozygous CB significantly improved 60-day neutrophil engraftment (hazard ratio (HR) 0.6; 95% confidence interval (CI) 0.4-0.9; p = .003). In paediatrics, HNK1 homozygous CB improved 60-day engraftment (HR 0.4; 95% CI 0.2-0.7; p = .003), as did MICA-129 methionine+ CB grafts (HR 1.7 95% CI 1.1-2.6; p = .02). CONCLUSION CB NKG2D and MICA genotypes potentially improve CB HSC engraftment. However, results contrast between adult and paediatric recipients and may reflect transplant procedure disparities between cohorts.
Collapse
Affiliation(s)
- Steven T Cox
- Anthony Nolan Research Institute, Royal Free Hospital, London, UK
- UCL Cancer Institute, Royal Free Campus, London, UK
| | - Warren Patterson
- Anthony Nolan Research Institute, Royal Free Hospital, London, UK
| | - Richard Duggleby
- Anthony Nolan Research Institute, Royal Free Hospital, London, UK
- UCL Cancer Institute, Royal Free Campus, London, UK
| | - Owen J R Jones
- Anthony Nolan Research Institute, Royal Free Hospital, London, UK
| | | | | | | | | | - Fernanda Volt
- Eurocord, Hôpital Saint Louis APHP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris Cité, Paris, France
| | - Éliane Gluckman
- Eurocord, Hôpital Saint Louis APHP, Institut de Recherche de Saint-Louis (IRSL) EA3518, Université de Paris Cité, Paris, France
| | - Richard Szydlo
- Anthony Nolan Research Institute, Royal Free Hospital, London, UK
- Department of Immunology and Inflammation, Imperial College London, London, UK
| | - Robert D Danby
- Anthony Nolan Research Institute, Royal Free Hospital, London, UK
- UCL Cancer Institute, Royal Free Campus, London, UK
- Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Diana Hernandez
- Anthony Nolan Research Institute, Royal Free Hospital, London, UK
- UCL Cancer Institute, Royal Free Campus, London, UK
| |
Collapse
|
2
|
Ratajczak M, Gluckman É, Gale RP. Hal E. Broxmeyer PhD: Experimental hematologist and umbilical cord blood cell transplant pioneer (27 November, 1944-8 December, 2021). Bone Marrow Transplant 2022. [PMID: 35217784 DOI: 10.1038/s41409-022-01576-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
| | | | - Robert Peter Gale
- Haematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, UK.
| |
Collapse
|
3
|
Gluckman É, Rafii H. [Hematopoietic stem cell transplant yesterday and today]. Soins 2021; 66:26-31. [PMID: 33962728 DOI: 10.1016/s0038-0814(21)00096-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Bone marrow transplant, more recently called hematopoietic stem cell transplant (HSC), is a complex medical procedure in which a patient with or without malignant hematologic disease receives a combination of chemoradiation followed by an injection of HSC, either from the same patient (autologous transplant) or from a healthy donor (allogeneic transplant).
Collapse
Affiliation(s)
- Éliane Gluckman
- Hôpital Saint-Louis, AP-HP, Eurocord, 1 avenue Claude-Vellefaux, 75010 Paris, France.
| | - Hanadi Rafii
- Hôpital Saint-Louis, AP-HP, Eurocord, 1 avenue Claude-Vellefaux, 75010 Paris, France
| |
Collapse
|